| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Apixaban: an Oral Direct Factor-Xa Inhibitor
|
Jiménez, David
|
|
2012
|
29 |
3 |
p. 187-201
|
artikel
|
| 2 |
Contribution of Endermology to Improving Indurations and Panniculitis/Lipoatrophy at Glatiramer Acetate Injection Site
|
Rubio Fernández, Delia
|
|
2012
|
29 |
3 |
p. 267-275
|
artikel
|
| 3 |
Cost per Treated Patient for Etanercept, Adalimumab, and Infliximab Across Adult Indications: a Claims Analysis
|
Bonafede, Machaon M. K.
|
|
2012
|
29 |
3 |
p. 234-248
|
artikel
|
| 4 |
Dipeptidyl Peptidase-4 Inhibitors in the Elderly: More Benefits or Risks?
|
Paolisso, Giuseppe
|
|
2012
|
29 |
3 |
p. 218-233
|
artikel
|
| 5 |
Exploring Channeling Optimized Radiofrequency Energy: a Review of Radiofrequency History and Applications in Esthetic Fields
|
Belenky, Inna
|
|
2012
|
29 |
3 |
p. 249-266
|
artikel
|
| 6 |
Phase 2 Study of Modified Irinotecan and Bolus 5-Fluorouracil/l-Leucovorin in Japanese Metastatic Colorectal Cancer Patients
|
Baba, Eishi
|
|
2012
|
29 |
3 |
p. 287-296
|
artikel
|
| 7 |
Sunitinib: the First to Arrive at First-Line Metastatic Renal Cell Carcinoma
|
Vázquez, Sergio
|
|
2012
|
29 |
3 |
p. 202-217
|
artikel
|
| 8 |
Uric Acid is an Important Predictor for Hypertensive Early Atherosclerosis
|
Mutluay, Ruya
|
|
2012
|
29 |
3 |
p. 276-286
|
artikel
|
Tijdschrift beschrijving